WO2025254047A1 - アンドロゲン受容体 rna配列に基づく新規二本鎖rna及びその利用 - Google Patents
アンドロゲン受容体 rna配列に基づく新規二本鎖rna及びその利用Info
- Publication number
- WO2025254047A1 WO2025254047A1 PCT/JP2025/019803 JP2025019803W WO2025254047A1 WO 2025254047 A1 WO2025254047 A1 WO 2025254047A1 JP 2025019803 W JP2025019803 W JP 2025019803W WO 2025254047 A1 WO2025254047 A1 WO 2025254047A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sequence
- double
- seq
- strand
- stranded rna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2/00—Peptides of undefined number of amino acids; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
Definitions
- This disclosure relates to double-stranded RNA, compositions containing the double-stranded RNA, and methods of using them. Specifically, it relates to double-stranded RNA used to suppress or inhibit tumor cell proliferation or metastasis, and compositions comprising the double-stranded RNA.
- This application claims priority to Japanese Patent Application No. 2024-092147, filed June 6, 2024, the entire contents of which are incorporated herein by reference.
- the androgen receptor (AR) is expressed in prostate cells, muscle cells, and hair papilla cells, and is closely involved in the growth of these cells. Meanwhile, androgen receptor expression is known to promote the progression of diseases such as prostate cancer and alopecia. Controlling androgen receptor expression is beneficial in the treatment of androgen receptor-related diseases such as prostate cancer and alopecia.
- JP 2007-215481 A and JP 2023-113845 A disclose siRNA that targets the androgen receptor or its related genes for the treatment of prostate cancer and the prevention of alopecia.
- nucleic acid drugs that target the androgen receptor are expected to have improved cell proliferation inhibitory effects.
- the primary objective of this disclosure is to provide technology that suppresses or inhibits cell proliferation by suppressing androgen receptor expression.
- the double-stranded RNA disclosed herein comprises a first strand and a second strand complementary to the first strand.
- the first strand is determined from a base sequence encoding an androgen receptor.
- the main sequence is the following sequence: CCUGGAUGGGGGCUCAUGGU (SEQ ID NO: 1); GGAUGGGGGCUCAUGGUGUU (SEQ ID NO: 2); GAUGGGGCUCAUGGUGUUU (SEQ ID NO: 3); GCCAUGGGCUGGCGAUCCU (SEQ ID NO: 4); GGCUGGCGAUCCUUCACCA (SEQ ID NO: 5); GAUCCUUCACCAAUGUCAA (SEQ ID NO: 6); Either and an additional sequence consisting of 2 to 4 bases added to the 3'-terminal side of the main sequence.
- the above-mentioned double-stranded RNA can function at least as small interfering RNA (siRNA).
- siRNA small interfering RNA
- RNAi RNA interference
- the second strand is composed of a main sequence complementary to the first strand and an additional sequence of 2 to 4 bases added to the 3' end of the complementary main sequence.
- double-stranded RNA can function favorably as siRNA, thereby more reliably inhibiting the proliferation of cells in which the androgen receptor is involved.
- the base sequence constituting the additional sequence is thymine-thymine (TT). This improves the stability of the double-stranded RNA.
- the cell type whose proliferation is inhibited by the composition is tumor cells. This allows for more reliable inhibition of cell proliferation.
- composition disclosed herein contains a peptide fragment that has cell membrane permeability, allowing it to pass through the cell membrane from the outside of the cell and introduce a foreign substance into the cytoplasm. This makes it easier to introduce double-stranded RNA into the target cell.
- the present disclosure provides a method for inhibiting the proliferation of at least one type of cell.
- One embodiment of the method disclosed herein comprises the steps of (1) preparing a composition disclosed herein and (2) supplying the composition to target cells in vitro. This makes it possible to inhibit the proliferation of cells associated with androgen receptor expression.
- the biological species of the cells is the same as the biological species containing the androgen receptor. This makes it possible to more reliably inhibit the proliferation of cells in which the androgen receptor is involved.
- 1 is a graph showing cell viability of lung cancer cells in one embodiment of the double-stranded RNA disclosed herein.
- 1 is a graph showing cell viability of neuroblastoma cells in one embodiment of the double-stranded RNA disclosed herein.
- polynucleotide refers to a polymer in which multiple (two or more) nucleotides are linked by phosphodiester bonds, and is not limited by the number of nucleotides.
- polynucleotides herein also include those containing both deoxyribonucleotides and nucleotides.
- artificially designed polynucleotides refer to polynucleotides whose nucleotide chains (full length) do not exist alone in nature, but are artificially synthesized by chemical synthesis or biosynthesis (i.e., production based on genetic engineering).
- first strand and second strand refer to one being the sense strand (or coding strand or passenger strand) and the other being the antisense strand (or template strand or non-coding strand or guide strand). That is, if the first strand is the sense strand, the second strand refers to the antisense strand. Also, if the second strand is the sense strand, the first strand refers to the antisense strand.
- the first strand and second strand may be fully complementary to each other, or may be at least partially complementary. That is, they may be capable of hybridizing at least under physiological conditions.
- the left side of a base sequence always indicates the 5'-end and the right side indicates the 3'-end.
- amino acid residue includes the N-terminal amino acid and C-terminal amino acid of a peptide chain, unless otherwise specified.
- the left side always indicates the N-terminal side and the right side indicates the C-terminal side.
- tumor is interpreted broadly and refers to tumors in general (typically malignant tumors), including carcinomas and sarcomas, as well as lesions of the blood or hematopoietic tissues (leukemia, lymphoma, etc.).
- tumor cells are synonymous with “cancer cells” and refer to cells that form such tumors, typically cells that have begun to grow abnormally independent of surrounding normal tissue (so-called cancerous cells). Therefore, unless otherwise specified, cells that are classified as tumor cells (cancer cells) rather than normal cells are referred to as tumor cells, regardless of their origin or properties.
- ⁇ Androgen receptor> is also referred to as AR or NR3C4.
- AR or NR3C4.
- this term is intended to encompass all synonyms, including naturally occurring androgen receptors and their variants.
- the animal species from which the androgen receptor is derived is not particularly limited, but is preferably the same as the animal species from which the double-stranded RNA or composition disclosed herein is to be delivered.
- a base sequence based on the base sequence of the androgen receptor may be used as the main sequence. While human-derived androgen receptors are described as a preferred example, the present technology can also be applied to androgen receptors derived from other animal species.
- the expression level of androgen receptors increases in cancer, alopecia (androgen pattern baldness), and other conditions.
- cancer examples include neuroblastoma, lung cancer, breast cancer, and prostate cancer.
- the double-stranded RNA and composition disclosed herein act favorably on cells in which the expression level of androgen receptors increases due to the above-mentioned diseases, and can inhibit their proliferation.
- the nucleotide sequence of the androgen receptor can be obtained from international databases. Examples of such international databases include the National Center for Biotechnology Information (NCBI), the European Nucleotide Archive (ENA), the DNA Data Bank of Japan (DDBJ), UniProt, and Ensembl. Specifically, the nucleotide sequence of the androgen receptor is provided by NCBI under accession number HQ692823, etc. The amino acid sequence of the androgen receptor is provided by Uniprot under accession number P10275, etc. AR-A, one of the androgen receptor isoforms described below, is provided by Uniprot under accession number P10275-2.
- the androgen receptor (AR-B) consists of 920 amino acid residues. It has eight exons. Exon 1 of the androgen receptor is located in the NTD (NH2-terminal domain), exons 2 and 3 are located in the DBD (DNA-binding domain), exons 3 and 4 are located in the Hinge (H) Region connecting the DBD and LBD (ligand-binding domain), and exons 4 to 8 are located in the LBD.
- the androgen receptor is a type of nuclear receptor that is activated when steroid hormones bind to the LBD in the cytoplasm. Activated androgen receptors translocate into the nucleus and are known to function as transcription factors that regulate the expression of various genes.
- AR-A also known as AR45
- AR-A has the amino acid residues 1 to 533 corresponding to exon 1 removed from AR-B (i.e., the full-length androgen receptor).
- AR-A consists of a DNA-binding domain, hinge region, ligand-binding domain, and C-terminal domain.
- seven amino acid residues on the N-terminal side (533rd to 539th amino acid residues in AR-B) have been replaced.
- the amino acid sequence of the human androgen receptor isoform AR-A is 388 amino acid residues as shown in SEQ ID NO: 7.
- the base sequence encoding this AR-A consists of 1,164 bases as shown in SEQ ID NO: 8.
- the double-stranded RNA of the present disclosure is a double-stranded RNA consisting of a first strand and a second strand complementary to the first strand.
- the first strand will be referred to as the sense strand and the second strand as the antisense strand, as will be described in detail.
- the sense strand is composed of a main sequence consisting of 19 to 23 bases, the 5'-terminal base of which is guanine (G) or cytosine (C), and an additional sequence consisting of 2 to 4 bases added to the 3'-terminal side of the main sequence.
- the main sequence is determined from the base sequence encoding the androgen receptor.
- the main sequence is typically composed of a polynucleotide, which is a polymer of ribonucleotides.
- the main sequence is composed of RNA. That is, the base sequence of the main sequence is typically represented by the four letters A (adenine), U (uracil), G (guanine), and C (cytosine), or the four letters a, u, g, and c.
- uracil can also be represented by T (thymine).
- the main sequence of the sense strand can be a partial base sequence of the base sequence encoding the androgen receptor. This allows the double-stranded RNA to function as siRNA (small interfering RNA) targeting the androgen receptor.
- siRNA small interfering RNA
- RNAi RNA interference
- siRNAi is a gene silencing process in which short double-stranded RNAs such as siRNAs suppress gene expression in a sequence-specific manner.
- siRNAs When siRNAs are introduced into cells, they form a complex with intracellular proteins called RISC (RNA-induced silencing complex). RISC binds to homologous sequences in mRNA transcribed from the target gene (here, the androgen receptor gene) and specifically cleaves the mRNA, thereby inhibiting translation.
- RISC RNA-induced silencing complex
- the main sequence is preferably selected from the base sequence encoding the androgen receptor, but one or more bases (e.g., two bases) may be substituted, deleted, and/or added (inserted) to other bases as long as the effects of the present technology are achieved.
- one or more bases e.g., two bases
- bases may be substituted, deleted, and/or added (inserted) to other bases as long as the effects of the present technology are achieved.
- the proportion of the base sequence encoding the androgen receptor in the main sequence is preferably 45% or more, and may be 60% or more, 75% or more, 90% or more, or 100% or more.
- the 5' end of the main sequence is preferably guanine or cytosine. Because guanine and cytosine have stronger binding strength with complementary strands than adenine and uracil, the 5' end of the sense strand (i.e., the 3' end of the antisense strand) is more stable. In other words, the 5' end of the antisense strand is relatively less stable. While the details of this mechanism are unclear, RISC, an RNAi-related protein, tends to preferentially incorporate the sense strand or antisense strand, whichever has the more energetically unstable 5' end.
- the antisense strand can be more easily incorporated into RISC, more effectively inducing RNAi. This allows the double-stranded RNA to function effectively as siRNA.
- the antisense strand is more easily taken up by RISC, allowing for more effective induction of RNAi.
- the GC content of the entire main sequence (the total proportion of G and C in the entire base sequence constituting the main sequence) is not particularly limited, but may be, for example, 20% to 75% or less, preferably 30% to 70% or less, or 40% to 68% or less.
- the GC content is a parameter related to the binding strength between the antisense strand taken up by RISC and the RNA comprising the main sequence, the ease of cleavage of the RNA, etc. With this GC content, the effect of RNAi can be efficiently exerted.
- the main sequence can be selected from 19 to 23 bases from G or C of the gene encoding the androgen receptor.
- the main sequence can be the following base sequence: CCUGGAUGGGGGCUCAUGGU (SEQ ID NO: 1); GGAUGGGGGCUCAUGGUGUU (SEQ ID NO: 2); GAUGGGGCUCAUGGUGUUU (SEQ ID NO: 3); GCCAUGGGCUGGCGAUCCU (SEQ ID NO: 4); GGCUGGCGAUCCUUCACCA (SEQ ID NO: 5); GAUCCUUCACCAAUGUCAA (SEQ ID NO: 6);
- the base sequences shown in SEQ ID NOs: 1 to 6 are all composed of RNA.
- SEQ ID NOs: 1 to 6 are all specific to androgen genes, and can avoid the risk of inhibiting translation of mRNA in host cells having a base sequence similar to the target sequence (so-called off-target effect).
- SEQ ID NOs: 23 to 28 are the base sequences of genes encoding androgen receptors corresponding to the RNA sequences of SEQ ID NOs: 1 to 6.
- the base sequence shown in SEQ ID NO:23 (the DNA sequence corresponding to the RNA sequence of SEQ ID NO:1) is the base sequence from bases 626 to 644 of the base sequence encoding the human androgen receptor (AR-A) (i.e., the sequence from the start codon to the stop codon).
- the base sequence shown in SEQ ID NO:24 (the DNA sequence corresponding to the RNA sequence of SEQ ID NO:2) is the base sequence from bases 629 to 647 of the base sequence encoding AR-A.
- the base sequence shown in SEQ ID NO:25 (the DNA sequence corresponding to the RNA sequence of SEQ ID NO:3) is the base sequence from bases 630 to 648 of the base sequence encoding AR-A.
- the base sequence shown in SEQ ID NO:26 (the DNA sequence corresponding to the RNA sequence of SEQ ID NO:4) is the base sequence from bases 649 to 667 of the base sequence encoding AR-A.
- the base sequence shown in SEQ ID NO:27 (the DNA sequence corresponding to the RNA sequence of SEQ ID NO:5) is the base sequence from bases 655 to 673 of the base sequence encoding AR-A.
- the base sequence shown in SEQ ID NO:28 (the DNA sequence corresponding to the RNA sequence of SEQ ID NO:6) is the base sequence from bases 662 to 680 of the base sequence encoding AR-A.
- the base sequences of SEQ ID NOs:1 to 6 are base sequences common to human androgen receptor isoforms (e.g., AR-A, AR-B).
- Double-stranded RNA consisting of the main sequences shown in SEQ ID NOs: 1 to 6 can suppress or inhibit the proliferation of at least one type of cell by supplying it to tumor cells (e.g., neuroblastoma, lung cancer, etc.). Typically, by supplying it to tumor cells, the proliferation of the tumor cells can be suppressed or inhibited. Note that androgen receptors are overexpressed in tumor cells compared to their expression in normal cells other than tumor cells. Therefore, even if the double-stranded RNA disclosed herein is supplied to normal cells, the presence of androgen receptors is so small that it is thought that the double-stranded RNA will have little effect.
- tumor cells e.g., neuroblastoma, lung cancer, etc.
- the sense strand of the double-stranded RNA disclosed herein may have an additional sequence consisting of 2 to 4 bases added to the 5'-end or 3'-end of the main sequence.
- the additional sequence is added to the 3'-end of the main sequence.
- the additional sequence is composed of polynucleotides (dimers, trimers, or tetramers).
- the polynucleotides that make up the additional sequence may be composed of only ribonucleotides, only deoxynucleotides, or both ribonucleotides and deoxynucleotides.
- the sense strand and antisense strand may be entirely RNA, or may be chimeric polynucleotides of RNA and DNA.
- the additional sequence may also contain modified deoxyribonucleotides, modified ribonucleotides, other known nucleotide analogs, etc.
- the base sequence constituting the additional sequence is not particularly limited, but preferably contains at least one base: adenine, uracil, or thymine. Furthermore, from the perspective of improving the stability of the double-stranded RNA, it is more preferable that the base sequence constituting the additional sequence is TT (thymine-thymine).
- the sense strand is composed of, for example, a base sequence of 21 to 27 bases, and may be composed of 21 to 25 bases, or 21 to 23 bases. In a preferred example, it is composed of 21 bases, consisting of a 19-base main sequence and a 2-base additional sequence. In such an example, RNAi can be effectively induced.
- the antisense strand has a base sequence complementary to the main sequence of the sense strand. This allows the antisense strand to hybridize with the sense strand, forming a double-stranded structure.
- the base sequence of the antisense strand may also be partially complementary to the main sequence of the sense strand. That is, one or more bases (e.g., two bases) of the antisense strand may be substituted, deleted, and/or added (inserted) with other bases. If the sense strand and the antisense strand can hybridize at least under physiological conditions, they can function as siRNA.
- the complementary base sequence portion is typically composed of a ribonucleotide polymer (RNA).
- the sense strand or antisense strand is typically composed of chemically unmodified ribonucleotides (RNA).
- the double-stranded RNA of the present disclosure may also contain DNA, chemically modified DNA or RNA, other known nucleotide analogs, etc., to the extent that it does not significantly impair the technology of the present disclosure. That is, one or more bases (e.g., two bases) in the sense strand or antisense strand may be substituted with chemically modified RNA (or DNA) such as methylated or pseudouridylated.
- chemically modified RNA include pseudouridine, N1-methylpseudouridine, 5-methylcytosine, and inosine.
- one or more bases (e.g., two bases) of uridine in the double-stranded RNA of the present disclosure can be substituted with pseudouridine.
- the antisense strand may be composed of a main sequence complementary to the sense strand and an additional sequence consisting of 2 to 4 bases added to the 5' or 3' end of the complementary main sequence.
- the additional sequence is preferably added to the 3' end of the complementary base sequence.
- the additional sequence of the antisense strand is added to the 3' end of the complementary base sequence.
- the configuration of the additional sequence in the antisense strand may be the same as the configuration of the additional sequence in the sense strand described above.
- the base sequence of the additional sequence in the antisense strand is the same as the additional sequence in the sense strand to which it hybridizes, but it may also be a different base sequence.
- the antisense strand is composed of a base sequence of, for example, 21 to 27 bases, and can be composed of 21 to 25 bases, or 21 to 23 bases.
- the antisense strand is composed of a base sequence of the same length as the sense strand, and all or part of the base sequence, excluding the additional sequence, is composed of a base sequence that is complementary to the main sequence of the sense strand.
- the antisense strand is composed of a base sequence of the same length as the sense strand, and all of the base sequence, excluding the additional sequence, is composed of a base sequence that is complementary to the main sequence of the sense strand.
- the sense and antisense strands constituting the double-stranded RNA disclosed herein can be produced according to common chemical synthesis methods. For example, they can be synthesized using a commercially available DNA/RNA automatic synthesizer. Alternatively, the sense and antisense strands may be synthesized in vitro or in vivo based on genetic engineering techniques. The synthesized sense and antisense strands are preferably purified, and can be purified, for example, by HPLC.
- the double-stranded RNA disclosed herein can be produced, for example, by annealing (hybridizing) a sense strand and an antisense strand.
- Annealing can be performed in accordance with conventional methods.
- annealing can be performed by mixing equal amounts of the sense strand and antisense strand in a solvent, heating at 90°C for 1 to 5 minutes, and then cooling to 4°C to room temperature.
- solvents that can be used include distilled water, pure water, ultrapure water, and buffers (e.g., HEPES-KOH buffer at pH 7.4, PBS, etc.).
- buffers e.g., HEPES-KOH buffer at pH 7.4, PBS, etc.
- double-stranded RNA also includes those in which the first strand and the second strand form a locally double-stranded structure via a loop structure.
- the double-stranded RNA can also be used as shRNA (short hairpin RNA) in another embodiment.
- shRNA is an RNA in which a main sequence and its complementary sequence exist on a single strand, and a loop sequence exists to form these loop structures.
- the shRNA has a loop structure, which allows the main sequence and its complementary sequence to hybridize and form a locally double-stranded structure. This allows the shRNA to be processed by Dicer, an enzyme present in cells, to form the siRNA of the above-mentioned embodiment.
- the structure of the shRNA may be the same as that of conventionally known shRNA.
- the length of the shRNA may be, for example, 50 to 70 bases.
- the length of the loop sequence may be, for example, 19 to 29 bases.
- the shRNA may be incorporated into a vector (e.g., a lentiviral expression vector). Use of the shRNA can stably induce RNAi in cells, thereby stably suppressing viral proliferation.
- compositions disclosed herein contain the double-stranded RNA described above.
- the compositions may contain various pharmaceutically acceptable carriers depending on the intended use.
- Preferred carriers include those commonly used in pharmaceuticals as diluents, excipients, etc.
- the carriers vary depending on the intended use and form of the composition. Typical examples include water, physiological buffer solutions, various organic solvents, etc.
- the carriers may also include aqueous solutions of alcohol (e.g., ethanol) at appropriate concentrations, glycerol, non-drying oils such as olive oil, or liposomes.
- Secondary components that may be contained in pharmaceutical compositions include various fillers, extenders, binders, humectants, surfactants, dyes, fragrances, etc.
- the compositions may also contain carriers used in conventional drug delivery systems (DDS).
- DDS drug delivery systems
- compositions disclosed herein are not particularly limited. Typical composition forms include solutions, suspensions, emulsions, aerosols, foams, granules, powders, tablets, capsules, and ointments. Furthermore, for injections and the like, the compositions may be freeze-dried or granulated, so that they can be dissolved in physiological saline or an appropriate buffer solution (e.g., PBS) immediately before use to prepare a medicinal solution. Furthermore, the process of preparing various forms of drugs (compositions) using double-stranded RNA (main component) and various carriers (minor components) may conform to conventionally known methods. Since such formulation methods do not characterize the present disclosure, detailed explanations are omitted. A source of detailed information regarding formulations is, for example, *Comprehensive Medicinal Chemistry*, edited by Corwin Hansch, published by Pergamon Press (1990).
- the composition disclosed herein inhibits the proliferation of at least one type of cell.
- the cells whose proliferation is inhibited are cells involved in the expression of androgen receptors, such as tumor cells (e.g., sarcoma, neuroblastoma, breast cancer cells, prostate cancer cells, etc.), hair follicle cells, fibroblasts, myocytes, epithelial cells, mesothelial cells, osteoblasts, etc.
- tumor cells e.g., sarcoma, neuroblastoma, breast cancer cells, prostate cancer cells, etc.
- hair follicle cells e.g., fibroblasts, myocytes, epithelial cells, mesothelial cells, osteoblasts, etc.
- the composition disclosed herein preferably inhibits the proliferation of tumor cells because the androgen receptor is overexpressed in these cells.
- the double-stranded RNA and composition disclosed herein can be preferably used as antitumor agents (anticancer agents) that suppress the proliferation of tumor cells
- composition disclosed herein includes, in addition to the double-stranded RNA described above, a peptide fragment (cell-penetrating peptide, CPP) with cell membrane permeability that allows it to pass through the cell membrane from outside the cell and introduce foreign substances into the cytoplasm.
- the peptide fragment is directly or indirectly bound (linked) to the double-stranded RNA disclosed herein to construct a construct of the peptide fragment and double-stranded RNA.
- double-stranded RNA is negatively charged and therefore cannot pass through the cell membrane.
- the construct of the peptide fragment and the double-stranded RNA can be introduced into the cytoplasm.
- the number of amino acid residues in the peptide fragment is not limited as long as cell membrane permeability is not impaired.
- linker is placed between the peptide fragment and the double-stranded RNA.
- the type of linker is not particularly limited. Typically, it is a peptidic linker, a non-peptidic linker, or the like.
- the method for binding the peptide fragment and the double-stranded RNA is not particularly limited, and can be carried out according to various conventionally known scientific techniques.
- composition disclosed herein comprises a peptide fragment and the double-stranded RNA disclosed herein.
- the double-stranded RNA does not have to be bound to the N- or C-terminus of the peptide fragment.
- the double-stranded RNA and the peptide fragment may form a complex, for example, through electrical or molecular interaction. This complex is more easily introduced into eukaryotic cells, allowing for efficient introduction of the double-stranded RNA.
- Nucleic acids such as double-stranded RNA are typically negatively charged. Therefore, the peptide fragment used preferably has a high proportion of basic amino acids and is positively charged. Furthermore, the proportion of the peptide fragment in this case may be 5 to 100 times the molar amount of the double-stranded RNA, preferably 40 to 60 times.
- the present disclosure may provide a method for inhibiting the proliferation of at least one type of cell using the composition disclosed herein, which includes the steps of preparing a composition of the present disclosure and delivering the composition to a target cell.
- composition disclosed herein may be prepared by a conventionally known method, for example, as described above.
- the composition disclosed herein is supplied to at least one type of cell (e.g., tumor cells) in a living body (in vivo) or outside the body (in vitro).
- the biological species of the supplied cells is not particularly limited and may be, for example, mammals, birds, amphibians, reptiles, fish, etc.
- the biological species from which the androgen receptor that forms the basis of the main sequence of the double-stranded RNA contained in the composition is derived is the same as the biological species of the target cells.
- the type of target cells is also not particularly limited, but is preferably tumor cells, more preferably neuroblastoma or lung cancer cells. Note that, although cells other than tumor cells may be present at the destination of the composition, the composition may be supplied only to the target cells (i.e., tumor cells).
- the method of administering the composition is not particularly limited and may be similar to methods conventionally used in animal treatment.
- the composition can be administered in vivo in a manner and dosage appropriate for its form and purpose.
- a liquid it can be administered in the desired amount to the affected area (e.g., malignant tumor tissue, virus-infected tissue, inflammatory tissue, etc.) of a patient or animal (i.e., a living organism) by intravenous, intralymphatic, intramuscular, subcutaneous, intradermal, or intraperitoneal injection.
- a solid form such as a tablet, or a gel or aqueous jelly such as an ointment
- a solid form such as a tablet, or a gel or aqueous jelly such as an ointment
- the affected area e.g., the affected area of a tissue or organ containing tumor cells, inflammatory cells, etc.
- a solid form such as a tablet can be administered orally.
- encapsulation or the application of a protective (coating) material is preferred to prevent degradation by digestive enzymes in the digestive tract.
- the amount of the composition to be supplied is not particularly limited.
- the lower limit of the amount of double-stranded RNA per kg of animal may be 0.01 mg or more, 0.05 mg or more, or 0.1 mg or more.
- the upper limit of the amount of double-stranded RNA per kg of animal may be, for example, 10 mg or less, 5 mg or less, or 1 mg or less.
- the amount of the composition to be supplied is not particularly limited.
- the lower limit of the double-stranded RNA concentration may be, for example, 1 nM or more, 5 nM or more, or 10 nM or more.
- the upper limit of the double-stranded RNA concentration in such culture medium may be, for example, 10 ⁇ M or less, 5 ⁇ M or less, 2 ⁇ M or less, 1 ⁇ M or less, or 100 nM or less.
- compositions disclosed herein can be delivered to the interior of target cells using known transfection methods. Examples include chemical gene transfer methods using cationic molecules (such as commercially available transfection reagents), physical transfer methods such as microinjection and electroporation, and biological gene transfer methods using viruses. Furthermore, as mentioned above, the compositions may also be delivered to the interior of cells using cell membrane-permeable peptide fragments.
- the sense strand of the siRNA in Sample 1 is composed of a main sequence consisting of SEQ ID NO: 1 (part of the base sequence encoding the human androgen receptor) and an additional sequence consisting of TT added to the 3' end of the main sequence.
- the sense strands of the siRNA in Samples 2 and 3 shown in Table 1 are composed of a main sequence consisting of SEQ ID NOs: 2 to 6 (part of the base sequence encoding the human androgen receptor) and an additional sequence consisting of TT added to the 3' end of the main sequence.
- the sense strand of the siRNA in Sample 7 is composed of a main sequence consisting of SEQ ID NO: 17 (a randomly artificially generated sequence) and an additional sequence consisting of TT added to the 3' end of the main sequence.
- the antisense strand in each example is composed of a sequence complementary to the main sequence and an additional sequence consisting of TT added to the 3' end of the sequence.
- the human lung cancer cell line A549 was used as the tumor cell.
- A549 cells were pre-cultured in a culture medium containing 10% fetal bovine serum (FBS) + E-MEM (Fujifilm Wako Pure Chemical Industries, Ltd., Cat. No. 051-07615) + 1% MEM non-essential amino acid solution (Fujifilm Wako Pure Chemical Industries, Ltd., Cat. No. 139-15651). Note that 0.5% penicillin-streptomycin (Fujifilm Wako Pure Chemical Industries, Ltd., Cat. No. 168-23191) was added to the culture medium only during pre-culture, but was not added during the following culture and evaluation.
- A549 cells adhered to the culture plate were washed with PBS, then a 0.25% trypsin/EDTA solution was added and incubated at 37°C for 2 minutes. After this incubation, the above-mentioned culture medium was added to inactivate the trypsin. The cells were then centrifuged at 150 x g for 5 minutes to precipitate. After removing the supernatant resulting from centrifugation, the above-mentioned culture medium was added to the precipitate (cell pellet) to prepare a cell suspension of approximately 5 x 10 4 cells/mL. Three commercially available 96-well plates were prepared, and the cell suspension was seeded into each well at 5 x 10 3 cells/100 ⁇ L/well. The plates were then incubated overnight at 37°C under 5% CO 2 .
- RNA solution adjusted to 2 mM with PBS was mixed with 75 ⁇ L of Opti-MEMTM to prepare Solution A.
- Opti-MEMTM was mixed with 75 ⁇ L of Opti-MEMTM to prepare Solution B.
- Equal amounts of Solution A and Solution B were mixed to prepare Solution C, which was then incubated at room temperature for 5 minutes.
- the prepared Solution C was added to wells containing cultured SK-N-SH cells at 11 ⁇ L/well (final siRNA concentration: 4 ⁇ M). The cells were then incubated at 37°C under 5% CO2 for 3 days.
- Cell proliferation was evaluated using Cell Counting Kit-8 (CCK-8, Dojin Kagaku Kenkyusho).
- CCK-8 Cell Counting Kit-8
- 10 ⁇ L of CCK-8 was added to each well, and the plate was incubated at 37°C and 5% CO2 for 1.5 hours.
- the absorbance at 450 nm for each well was measured.
- the absorbance was the average of three wells.
- a blank well containing only the culture medium and CCK-8 reagent was set up. The measured value for Sample 1 was determined by subtracting the absorbance of the blank from the absorbance of Sample 1.
- Samples 2, 3, and 6 were prepared in the same manner as Sample 1, except that the siRNA in Sample 1 was replaced with the siRNA for Samples 2, 3, and 6 shown in Table 1.
- Comparative Example The comparative example was the same as Sample 1, except that a PBS solution was used instead of the RNA solution in Sample 1. In other words, no siRNA was introduced in the comparative example.
- Untreated wells were prepared in the same manner as in Example 1, except that the RNA solution and LipofectamineTM RNAiMAX were not added.
- the cell viability in each test example is expressed as a percentage, with the measured value for the untreated well set at 100%, and is shown in Figure 1.
- samples 1-3 and 6 had significantly lower cell viability than the comparative example. Furthermore, of these, the siRNA in samples 1-3 was particularly effective in inhibiting the proliferation of lung cancer cells. Therefore, it is believed that the siRNA in samples 1-3 and 6 has the function of inhibiting the proliferation of tumor cells (here, lung cancer cells).
- ⁇ Cell proliferation test of SK-N-SH strain The tumor cells used were the SK-N-SH strain, a human neuroblastoma cell line. Cell proliferation was evaluated by removing the 96-well plate in which the SK-N-SH cells had been cultured on day 4 (day 2 after siRNA addition), adding 10 ⁇ L of CCK-8 to each well, and incubating for 2.0 hours at 37°C in 5% CO2. The rest of the experiment was performed in the same manner as in the cell proliferation test using human lung cancer cells (A594 strain). The cell viability in each test example is expressed as a percentage of the measured value for the untreated well, which is set at 100%, and is shown in Figure 2.
- Samples 3 to 7 were prepared in the same manner as Sample 1, except that the siRNA in Sample 1 was changed to the siRNA of Samples 3 to 7 shown in Table 1.
- the cell viability of samples 3 to 6 was reduced, significantly lower than that of the comparative example. This suggests that the siRNA in samples 3 to 6 has the function of inhibiting the proliferation of tumor cells (neuroblastoma cells).
- the base sequence shown in SEQ ID NO: 29 is a randomly and artificially created base sequence.
- Sample 7 has SEQ ID NO: 29 as its main sequence, and did not affect cell proliferation. Therefore, in comparison with sample 7, samples 3 to 6 are considered to be specific to the human androgen receptor gene. For this reason, the siRNA in samples 3 to 6 avoids off-target effects, does not affect other organs, and is therefore expected to be suitable for clinical application.
- Item 1 A double-stranded RNA consisting of a first strand and a second strand complementary to the first strand, the double-stranded RNA comprising: a main sequence determined from a base sequence encoding the androgen receptor; and an additional sequence consisting of 2 to 4 bases added to the 3'-terminal side of the main sequence, CCUGGAUGGGGGCUCAUGGU (SEQ ID NO: 1); GGAUGGGGGCUCAUGGUGUU (SEQ ID NO: 2); GAUGGGGCUCAUGGUGUUU (SEQ ID NO: 3); GCCAUGGGCUGGCGAUCCU (SEQ ID NO: 4); GGCUGGCGAUCCUUCACCA (SEQ ID NO: 5); GAUCCUUCACCAAUGUCAA (SEQ ID NO: 6); A double-stranded RNA, which is either
- Item 2 The double-stranded RNA described in Item 1, wherein the second strand comprises a main sequence complementary to the first strand and an additional sequence consisting of 2 to 4 bases added to the 3' end of the complementary main sequence.
- Item 3 The double-stranded RNA according to Item 1 or 2, wherein the base sequence constituting the additional sequence is thymine-thymine (TT).
- TT thymine-thymine
- Item 4 A composition that inhibits the proliferation of at least one type of cell, comprising the double-stranded RNA described in any one of Items 1 to 3.
- Item 5 The composition described in Item 4, wherein the cells are tumor cells.
- Item 6 The composition according to Item 4 or 5, comprising a peptide fragment having cell membrane permeability that allows a foreign substance to be introduced into the cytoplasm by passing through the cell membrane from the outside of the cell.
- Item 7 A method for inhibiting the proliferation of at least one type of cell, comprising: A preparation step of preparing the composition according to any one of items 4 to 6; and providing said composition to said cells in vitro.
- Item 8 The method according to Item 8, wherein the biological species of the cells is the same as the biological species containing the androgen receptor.
- the double-stranded RNA disclosed herein can inhibit (or suppress) cell proliferation. Therefore, by using this double-stranded RNA, it is possible to provide a composition (e.g., an anti-tumor agent) that inhibits the proliferation of at least one type of cell (e.g., tumor cells).
- a composition e.g., an anti-tumor agent
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025561320A JPWO2025254047A1 (cg-RX-API-DMAC7.html) | 2024-06-06 | 2025-06-02 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024092147 | 2024-06-06 | ||
| JP2024-092147 | 2024-06-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2025254047A1 true WO2025254047A1 (ja) | 2025-12-11 |
Family
ID=97961167
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP2025/019803 Pending WO2025254047A1 (ja) | 2024-06-06 | 2025-06-02 | アンドロゲン受容体 rna配列に基づく新規二本鎖rna及びその利用 |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JPWO2025254047A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2025254047A1 (cg-RX-API-DMAC7.html) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008035291A2 (en) * | 2006-09-21 | 2008-03-27 | Gen-Med S.A. | A double stranded rna oligonucleotide: a pharmaceutical or cosmetic composition containing it and its use as an active pharmaceutical ingredient in the treatment of androgen-related diseases |
| US20130142875A1 (en) * | 2011-11-14 | 2013-06-06 | Silenseed Ltd. | Methods and compositions for treating prostate cancer |
| JP2013534424A (ja) * | 2010-07-06 | 2013-09-05 | ダイセルナ ファーマシューティカルズ, インコーポレイテッド | 二本鎖rnaによるアンドロゲン受容体の特異的阻害に対する方法と化合物 |
| JP2020520961A (ja) * | 2017-05-24 | 2020-07-16 | サイレンシード リミテッド | がん免疫療法のための組成物及び方法 |
| WO2023171820A1 (ja) * | 2022-03-11 | 2023-09-14 | 日本新薬株式会社 | キャリアペプチドが連結された核酸 |
-
2025
- 2025-06-02 JP JP2025561320A patent/JPWO2025254047A1/ja active Pending
- 2025-06-02 WO PCT/JP2025/019803 patent/WO2025254047A1/ja active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008035291A2 (en) * | 2006-09-21 | 2008-03-27 | Gen-Med S.A. | A double stranded rna oligonucleotide: a pharmaceutical or cosmetic composition containing it and its use as an active pharmaceutical ingredient in the treatment of androgen-related diseases |
| JP2013534424A (ja) * | 2010-07-06 | 2013-09-05 | ダイセルナ ファーマシューティカルズ, インコーポレイテッド | 二本鎖rnaによるアンドロゲン受容体の特異的阻害に対する方法と化合物 |
| US20130142875A1 (en) * | 2011-11-14 | 2013-06-06 | Silenseed Ltd. | Methods and compositions for treating prostate cancer |
| JP2020520961A (ja) * | 2017-05-24 | 2020-07-16 | サイレンシード リミテッド | がん免疫療法のための組成物及び方法 |
| WO2023171820A1 (ja) * | 2022-03-11 | 2023-09-14 | 日本新薬株式会社 | キャリアペプチドが連結された核酸 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPWO2025254047A1 (cg-RX-API-DMAC7.html) | 2025-12-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2821085B1 (en) | Rna interference for the treatment of gain-of-function disorders | |
| JP2023013932A (ja) | SARS-CoV-2 RNA配列に基づく新規siRNA及びその利用 | |
| JP2009514877A (ja) | siRNAの送達媒体としてのペプチド−ダイザ基質RNA抱合体 | |
| TW201249991A (en) | Modulation of TIMP1 and TIMP2 expression | |
| WO2010006239A2 (en) | Regulation of apoptosis by neural specific splice variants of ig20 | |
| JP2022541212A (ja) | 治療的使用のための、ヒト遺伝子JAK1又はJAK3の発現を標的とするSiRNA配列 | |
| WO2013056670A1 (zh) | 小干扰RNA及其应用和抑制plk1基因表达的方法 | |
| WO2004007721A1 (en) | Conjugate for double-stranded rna sequence releasing and methods thereof | |
| WO2025159163A1 (ja) | App rna配列に基づく新規二本鎖rna及びその利用 | |
| WO2025234433A1 (ja) | Semaphorin-3a rna配列に基づく新規二本鎖rna及びその利用 | |
| WO2025142999A1 (ja) | ペリオスチン rna配列に基づく新規二本鎖rna及びその利用 | |
| WO2026048822A1 (ja) | Mapt rna配列に基づく新規二本鎖rna及びその利用 | |
| WO2026028973A1 (ja) | L-pgds rna配列に基づく新規二本鎖rna及びその利用 | |
| WO2026048718A1 (ja) | Psapを標的とした二本鎖rna及びその利用 | |
| WO2026088997A1 (ja) | Tdp-43を標的とした二本鎖rna及びその利用 | |
| US20100286244A1 (en) | RNAi MEDIATED KNOCKDOWN OF NUMA FOR CANCER THERAPY | |
| WO2025110115A1 (ja) | Cxcl12 rna配列に基づく新規二本鎖rna及びその利用 | |
| WO2025143001A1 (ja) | C5 rna配列に基づく新規二本鎖rna及びその利用 | |
| WO2025143000A1 (ja) | C3 rna配列に基づく新規二本鎖rna及びその利用 | |
| KR20080044909A (ko) | 세포 내로 리보핵산의 전달을 위한 약학 조성물 | |
| WO2011074652A1 (ja) | HIF-2αの発現を抑制する核酸 | |
| WO2024190329A1 (ja) | 組成物およびその利用 | |
| WO2024190328A1 (ja) | 組成物およびその利用 | |
| WO2026028971A1 (ja) | Rsv-b rna配列に基づく新規二本鎖rna及びその利用 | |
| WO2026083945A1 (ja) | Rsv nタンパク質 rna配列に基づく新規二本鎖rna及びその利用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ENP | Entry into the national phase |
Ref document number: 2025561320 Country of ref document: JP Kind code of ref document: A |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2025561320 Country of ref document: JP |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 25819805 Country of ref document: EP Kind code of ref document: A1 |